Boston Scientific Corp (BSX)vsAnheuser Busch Inbev NV ADR (BUD)
BSX
Boston Scientific Corp
$53.93
-4.67%
HEALTHCARE · Cap: $84.08B
BUD
Anheuser Busch Inbev NV ADR
$79.89
-0.45%
CONSUMER DEFENSIVE · Cap: $159.00B
Smart Verdict
WallStSmart Research — data-driven comparison
Anheuser Busch Inbev NV ADR generates 196% more annual revenue ($60.96B vs $20.61B). BSX leads profitability with a 17.3% profit margin vs 11.9%. BSX appears more attractively valued with a PEG of 0.68. BSX earns a higher WallStSmart Score of 71/100 (B).
BSX
Strong Buy71
out of 100
Grade: B
BUD
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-22.6%
Fair Value
$46.16
Current Price
$53.93
$7.77 premium
Margin of Safety
-9.4%
Fair Value
$70.63
Current Price
$79.89
$9.26 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Strong operational efficiency at 20.6%
Large-cap with strong market position
Strong operational efficiency at 26.7%
Earnings expanding 20.3% YoY
Areas to Watch
No major concerns identified
Expensive relative to growth rate
Trading at 10.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : BUD
The strongest argument for BUD centers on Market Cap, Operating Margin, EPS Growth. Revenue growth of 12.0% demonstrates continued momentum.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Bear Case : BUD
The primary concerns for BUD are PEG Ratio, Price/Book.
Key Dynamics to Monitor
BSX profiles as a mature stock while BUD is a value play — different risk/reward profiles.
BUD carries more volatility with a beta of 0.79 — expect wider price swings.
BUD is growing revenue faster at 12.0% — sustainability is the question.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BSX scores higher overall (71/100 vs 63/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Anheuser Busch Inbev NV ADR
CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA
Anheuser-Busch InBev SA / NV is engaged in the production, distribution and sale of beer, alcoholic beverages and soft drinks worldwide.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?